Your browser doesn't support javascript.
loading
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Cameron, David; Piccart-Gebhart, Martine J; Gelber, Richard D; Procter, Marion; Goldhirsch, Aron; de Azambuja, Evandro; Castro, Gilberto; Untch, Michael; Smith, Ian; Gianni, Luca; Baselga, Jose; Al-Sakaff, Nedal; Lauer, Sabine; McFadden, Eleanor; Leyland-Jones, Brian; Bell, Richard; Dowsett, Mitch; Jackisch, Christian.
Afiliación
  • Cameron D; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. Electronic address: d.cameron@ed.ac.uk.
  • Piccart-Gebhart MJ; Department of Medicine, Université Libre de Bruxelles, Brussels, Belgium.
  • Gelber RD; BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, B
  • Procter M; Frontier Science Scotland Ltd, Kincraig, Kingussie, UK.
  • Goldhirsch A; European Institute of Oncology, Milan, Italy.
  • de Azambuja E; Medical Oncology Clinic, Université Libre de Bruxelles, Brussels, Belgium.
  • Castro G; Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Untch M; Helios Klinikum Berlin Buch, Multidisciplinary Breast Cancer Center, Berlin, Germany.
  • Smith I; Breast Unit, Royal Marsden Hospital, and The Institute of Cancer Research, London, UK.
  • Gianni L; Department of Medical Oncology, San Raffaele Hospital, Scientific Institute, Milan, Italy.
  • Baselga J; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Al-Sakaff N; F Hoffmann-La Roche, Basel, Switzerland.
  • Lauer S; F Hoffmann-La Roche, Basel, Switzerland.
  • McFadden E; Frontier Science Scotland Ltd, Kincraig, Kingussie, UK.
  • Leyland-Jones B; Avera Cancer Institute Center for Precision Oncology, Sioux Falls, SD, USA.
  • Bell R; Deakin University, Waurn Ponds, VIC, Australia.
  • Dowsett M; Breast Unit, Royal Marsden Hospital, and The Institute of Cancer Research, London, UK.
  • Jackisch C; Department of Gynecology and Obstetrics, Sana Klinikum Offenbach, Offenbach, Germany.
Lancet ; 389(10075): 1195-1205, 2017 03 25.
Article en En | MEDLINE | ID: mdl-28215665
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Biomarcadores de Tumor / Receptor ErbB-2 / Trastuzumab / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Año: 2017 Tipo del documento: Article